• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：细胞治疗中的淋巴细胞：CAR-T细胞的功能调节

Corrigendum: Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells.

作者信息

Dwivedi Alka, Karulkar Atharva, Ghosh Sarbari, Rafiq Afrin, Purwar Rahul

机构信息

Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India.

出版信息

Front Immunol. 2019 Mar 8;10:401. doi: 10.3389/fimmu.2019.00401. eCollection 2019.

DOI:10.3389/fimmu.2019.00401
PMID:30906295
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6418378/
Abstract

[This corrects the article DOI: 10.3389/fimmu.2018.03180.].

摘要

[本文更正了文章的数字对象标识符：10.3389/fimmu.2018.03180。]

相似文献

1
Corrigendum: Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells.勘误：细胞治疗中的淋巴细胞：CAR-T细胞的功能调节
Front Immunol. 2019 Mar 8;10:401. doi: 10.3389/fimmu.2019.00401. eCollection 2019.
2
Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.勘误：实体瘤中的嵌合抗原受体T细胞疗法：挑战与临床应用
Front Immunol. 2019 Apr 17;10:780. doi: 10.3389/fimmu.2019.00780. eCollection 2019.
3
Corrigendum: Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers.勘误：胆管癌、胰腺癌和胃癌中CAR T细胞疗法的进展
Front Immunol. 2022 Dec 20;13:1082984. doi: 10.3389/fimmu.2022.1082984. eCollection 2022.
4
Corrigendum: Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments.勘误：基于配体的嵌合抗原受体T细胞：未来新疗法中驱动T细胞的不同策略。
Front Immunol. 2022 Nov 21;13:1078003. doi: 10.3389/fimmu.2022.1078003. eCollection 2022.
5
Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.勘误：靶向肿瘤MUC1糖蛋白的嵌合抗原受体T细胞可降低三阴性乳腺癌的生长。
Front Immunol. 2020 Dec 7;11:628776. doi: 10.3389/fimmu.2020.628776. eCollection 2020.
6
Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.白细胞介素武装嵌合抗原受体修饰 T 细胞用于癌症免疫治疗。
Gene Ther. 2018 Jun;25(3):192-197. doi: 10.1038/gt.2017.81. Epub 2017 Sep 21.
7
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.勘误：在滤泡性淋巴瘤患者接受嵌合抗原受体T细胞治疗后，通过可追踪突变的特定特征对循环肿瘤DNA进行个性化监测。
Front Immunol. 2023 Aug 16;14:1243241. doi: 10.3389/fimmu.2023.1243241. eCollection 2023.
8
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.勘误：嵌合抗体14.18联合GM-CSF、IL-2和异维A酸用于清髓性治疗后高危神经母细胞瘤患者的综合安全性试验：儿童肿瘤学组研究ANBL0931。
Front Immunol. 2018 Jul 16;9:1641. doi: 10.3389/fimmu.2018.01641. eCollection 2018.
9
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.勘误：在滤泡性淋巴瘤患者接受嵌合抗原受体T细胞治疗后，通过可追踪突变的特定特征对循环肿瘤DNA进行个性化监测。
Front Immunol. 2024 Jan 10;14:1349296. doi: 10.3389/fimmu.2023.1349296. eCollection 2023.
10
Chimeric antigen receptor-engineered T-cell therapy for liver cancer.嵌合抗原受体修饰的 T 细胞治疗肝癌。
Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. doi: 10.1016/j.hbpd.2018.05.005. Epub 2018 May 24.

引用本文的文献

1
Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development.探索肿瘤免疫疗法在药物研发中的复杂性和前景。
Int J Mol Sci. 2024 Jun 11;25(12):6444. doi: 10.3390/ijms25126444.
2
Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy.重新定义结直肠癌之战：新兴免疫疗法及其临床疗效的全面综述。
Front Immunol. 2024 Mar 12;15:1350208. doi: 10.3389/fimmu.2024.1350208. eCollection 2024.
3
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy.免疫疗法及其在妇科（卵巢、子宫内膜和宫颈）肿瘤中的发展：从免疫检查点抑制剂到嵌合抗原受体（CAR）-T细胞疗法。
Cancers (Basel). 2021 Feb 17;13(4):840. doi: 10.3390/cancers13040840.